

AWARD NUMBER: W81XWH-19-1-0807

TITLE: Targeting the Gut Microbiome to Treat Post-Traumatic Osteoarthritis

PRINCIPAL INVESTIGATOR: Michael Zuscik, PhD

CONTRACTING ORGANIZATION: University of Colorado at Denver, Aurora, CO

REPORT DATE: October 2021

TYPE OF REPORT: Annual Report

PREPARED FOR: U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE October 2021		2. REPORT TYPE Annual Report		3. DATES COVERED 15Sep2020-14Sep2021	
4. TITLE AND SUBTITLE Targeting the Gut Microbiome to Treat Post-Traumatic Osteoarthritis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-19-1-0807	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Partnering PIs- Steven Gill, PhD and Michael Zuscik, PhD E-Mail: STEVEN_GILL@URMC.ROCHESTER.EDU ; MICHAEL.ZUSCIK@CUANSCHUTZ.EDU				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Colorado at Denver, Aurora, CO				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT While osteoarthritis (OA) is a debilitating condition with no disease modifying treatments, the gut microbiome may play a role in its development and progression. The establishment of a disease modifying treatment of OA has immense ramifications, including improved quality of life, lowered economic burden of treatment, and increased productivity of patients with OA. The purpose of this project is to study the disease enhancing role of the gut microbiome in the development of OA as well as to develop microbiome-targeting treatments of the disease. Fecal microbiota transplants (FMTs) will be used to examine the causal relationship between microbiome dysbiosis that may develop in veterans diagnosed with post-traumatic osteoarthritis (PTOA) and belonging to the Military and Veteran Microbiome: Consortium for Research and Education (MVM-CoRE). Treatment of PTOA with microbiome pre and probiotics has been ongoing, and we find the dietary supplement hydrolyzed hylaline cartilage (hHC) to have protective effects on cartilage degeneration in a mouse model of PTOA. Some of this data was presented in our technical report last year, and it is now developed adequately to be in a manuscript to be submitted this fall (Fall 2021). Despite residual institutional shutdowns caused by the COVID-19 pandemic, significant progress has been made on the first two objectives of this project, with progress expected to continue apace on all objectives.					
15. SUBJECT TERMS None listed.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 32	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	6
5. Changes/Problems	6
6. Products	7
7. Participants & Other Collaborating Organizations	8
8. Special Reporting Requirements	12
9. Appendix 1	13
10. Appendix 2	14
11. Appendix 3	15
12. Appendix 4	30

1. Introduction

This project is focused on 1) studying the disease causing role of the gut microbiome in the development of osteoarthritis (OA), and 2) developing approaches that target the gut microbiome to treat posttraumatic OA (PTOA), a disease that does not currently have an accepted disease modifying treatment. Our first objective is to study the microbiome dysbiosis that develops in a mouse model of PTOA and military veterans that have been diagnosed with PTOA and have been recruited into the Military and Veteran Microbiome: Consortium for Research and Education (MVM-CoRE). To prove the causal role of this dysbiosis, fecal microbiota transplants (FMTs) are planned (mouse to mouse or human to mouse), and specific, potentially pathogenic, microbial species will be gavaged to pinpoint taxa that are PTOA-accelerating. Our second objective is to build on our historical work studying dietary supplements as disease modifiers for OA by examining the impact of daily supplementation with hydrolyzed hyaline cartilage (hHC) on PTOA progression and on the gut microbiome. Again, FMTs between supplemented and non-supplemented mice will test the causal role of the gut community in any joint protection that is observed, and specific microbial species will be studied as active participants in the protective effects. Finally, in the third objective, we will focus on developing pre- and probiotic combinations for dietary supplements involving hHC and taxa identified in the second objective that promote joint protection and decelerated PTOA progression. Multiple dosing regimens will be tested, with the most protective combinations studied with deep analysis of the gut microbiome using cutting edge metagenomic, metatranscriptomic, and metabolomic profiling to focus on specific molecular fractions that are contributing to disease modification that we document. We have completed two years of work on this project, and despite a major interruption by the COVID-19 pandemic, we have continued to make progress in the first and second objectives. This progress is described below in the various sections of this report.

Note: This report provides information on the second year of a partnering-PI project, and the specific activity for each aspect of progress is attributed to the contributing PI (CU for Zuscik, UR for Gill). In general, all OA analysis, animal work, and human work occurs at CU. All analysis of gut microbiome and microbiology work to expand and maintain taxa of interest is performed at UR.

2. Key Words

Osteoarthritis (OA)
Posttraumatic osteoarthritis (PTOA)
Gut microbiome
Fecal microbiota transplant (FMT)
Military and Veteran Microbiome: Consortium for Research and Education (MVM-CoRE)
Hydrolyzed hyaline cartilage (hHC)
Destabilization of the medial meniscus (DMM)
Peptococcaceae rc4-4
Anaeroplasmataceae
Firmicutes
Tenericutes
Cartilage
Chondrocyte
Synovium
Tumor Necrosis Factor-alpha (TNF)

3. Accomplishments

- What were the major goals of the project?

The major goals of the project are 1) to define the role of the gut microbiome in PTOA, 2) to establish that hHC-induced chondroprotection in PTOA is due to effects on the gut microbiome, and 3) to test the efficacy of combined pre- and probiotic strategies to treat PTOA. Our aim is to accomplish these goals using state-of-the-

art approaches and methods, culminating with a dataset supporting the effectiveness of gut microbiome interventions in treating PTOA and setting the stage for the first in-human trial work to test targeting of the gut microbiome as an OA disease modifying approach.

- What was accomplished under these goals?

i) Experiments have been performed to study the gut microbiome dysbiosis that occurs in PTOA (Objective #1). Using a mouse model of PTOA that requires surgical destabilization of the medial meniscus (DMM) to initiate PTOA, we have collected fecal samples weekly for 16s rDNA analysis, for study of the metagenome, and for study of the metabolome. DMM surgeries were initially performed on a cohort of mice in January of 2020, but these samples were destroyed when the COVID-19 pandemic caused CU and UR to shut down operations in March of 2020. Mice, which were in mid-protocol, were euthanized because of the shutdown, essentially rendering collected samples unusable since the full experiment could not be performed. Once the Universities re-opened in the summer of 2020, a new cohort of mice was purchased, and DMMs were performed again in September of 2020. Collection protocols proceeded (CU), and terminal endpoints in December 2020 and January of 2021 provided fecal and cecal samples that we have been analyzing. Microbial 16S rDNA has been carried out (UR), and a dysbiosis was observed in the mice (see Appendix 1), setting the stage for follow-on transcriptome analyses (UR) and metabolomic profiling (CU). These follow-on analyses are ongoing at the time of this report's submission.

ii) To support humanization FMT experiments (Objective #1), an IRB was developed within the MVM-CoRE to collect fecal material from veterans with diagnosed advanced knee osteoarthritis that are otherwise healthy. This IRB was originally approved in February of 2020, leading to the planned initiation to obtain HRPO approval. The COVID-19 shutdown in March of 2020 prevented the submission of the HRPO protocol because all human study was suspended, and it was clear a modified protocol would need to be developed with consideration around protections for human participants in the context of the pandemic. Human research restarted in August of 2020 with a broad range of new requirements for COVID-19 protections, and we proceeded to make modification to our human protocol accordingly. The modifications were submitted in September of 2020, and we spent the bulk of the ensuing months awaiting approval from the local VA IRB, followed by the Colorado Multiple Institution Review Board (COMIRB). Those approvals were finally granted in September of 2021, with the paperwork submitted for HRPO review and approval on September 27, 2021. The delay of human research across institutions caused by the pandemic has significantly impacted progress on this aspect of the project, driving our rationale for requesting a 1-year NCE. Our aim now is to collect (CU) and analyze (UR) fecal samples collected from veterans with OA in the first half of 2022, and then and employ these samples in mouse FMT experiments starting in the fall of 2022.

iii) We initiated work with hHC supplements immediately after receiving IACUC and ACURO approval in September of 2019 (Objective #2). Despite the intervening pandemic-related shutdown, this work has led to a dataset that was presented at the 2020 American Society for Bone and Mineral Research virtual conference, with an updated version of the dataset presented at the Orthopedic Research Symposium and D'Ambrosia Diversity Lectureship at the University of Colorado (regional meeting, Appendix 1). The findings are currently in preparation as a manuscript (CU and UR). This study, which involved quantifying the impact of hHC on PTOA (CU), provides the first data delineating the impact of the gut microbiome of this supplement (UR), setting the stage for our ongoing studies which involve isolation and expansion of several interesting taxa for *in vivo* work as a probiotic intervention (CU and UR). The net results of this study were collected in the broader context of our work to study the role of the gut microbiome in the action of various nutraceutical products that led to a publication in 2020, and a follow-on White Paper in press at Current Rheumatology Reports at Springer Nature (Appendix 2).

- What opportunities for training and professional development have the project provided?

During year 2, we had two trainees that were involved in this project: predoctoral student David Villani and postdoctoral fellow Honey Hendesi MD PhD (recently promoted to Instructor -September of 2021). We had another postdoctoral fellow on the team last year (Andrew Wu MD), but he graduated from the program and is currently in an Orthopaedic Residency at Johns Hopkins. We also have technical-level staff (Jake Guzzetti)

and a young faculty (Lacey Favazzo PhD) that help carry forward the work. These individuals are involved in all aspects of the management and execution of the experimental plan, and thus gain knowledge on how to administer a program of research, how to consider budgets in the context of the work, and scientific aspects of the project. The training and professional development plays out in daily work on the project, weekly work in progress meetings and journal clubs, and ultimately in the presentation of the work in broader contexts (e.g. the American Society of Bone and Mineral Research conference mentioned above).

Education is an important component to the overall plan, and our work on this project dovetails with the broader plan to develop a formal training program in musculoskeletal biology. To that end, we have submitted a T32 training grant application to NIAMS this is to be reviewed in the fall of 2021.

- How were the results disseminated to communities of interest?

Besides the 2 publications so far, the posters at the 2020 ASBMR and the Regional Symposium are our primary modes of dissemination. Some of the work was also presented in an oral presentation at the Steadman Philippon Research Institute Science Summit in Vail, Colorado on August 21, 2021 as well.

- What do you plan to do in the next reporting period to accomplish the goals?

With the delay in obtaining human fecal material, which is required for the mouse humanization experiment, we now project completion of the experiments outline in Objective #1 in the coming year, with analyses of these data taking place as we transition into the NCE year, year 4. We will also complete Objective 2, setting the stage for initiation of experiments in Objective 3, which will commence in the fall of 2022. The team is intact, and now fully working collaboratively, so we are confident that we will recover from setbacks related to the COVID-19 shutdown that occurred in 2020.

4. Impact

- What was the impact on development of the principal disciplines of the project?

The central impact of the work so far: data generated on this project have provided the first evidence to suggest that nutraceutical supplements may impact joint health and OA degenerative disease via effects on the gut microbiome (see appendix 3). This is a novel concept that provides the first explanation for the purported effects of such agents in the context of joint homeostasis and disease.

- What was the impact on other disciplines?

Nothing to report

- What was the impact on technology transfer?

Nothing to report

- What was the impact on society beyond science and technology?

Nothing to report

5. Changes/Problems

- Changes in approach and reasons for change.

Nothing to report

- Actual or anticipated problems or delays and action plans to resolve them

As mentioned, the COVID-19 pandemic has impacted our progress on the project. Research activity at both CU and UR was completely shut down from mid-March of 2020 to June of 2020, with the months between June and August only leading to incremental increases in campus occupancy and lab/vivarium activity. Human studies were delayed even further, through to September of 2021, due to concerns about community spread, the lagging development of consensus on mitigation of spread, and a delay in IRB panels from approving studies that could expose participants to disease risk. Our human protocol required amendments to move forward because of new policies and procedures that needed to be incorporated into the plan. As mentioned, amendments have just recently been approved by the VA IRB and the COMIRB, and we have submitted the final paperwork to HRPO for DOD approval (submitted September 27, 2021)

Note: There are no anticipated additional delays in the project moving forward.

- Changes that have significant impact on expenditures

As mentioned, a mouse experiment that was initiated in late 2019 had to be terminated due to the pandemic. Lost costs included the initial purchase of the mice and the per diems for vivarium housing up until the date the colony was euthanized. Summary expenses: 60 male mice + per diems: \$1,774.80.

- Significant changes in use and care of human subjects, vertebrate animals, biohazards, and/or select agents.

Nothing to report

6. Products

- Publications, conference papers and presentations

a. Publications:

Favazzo LJ, Hendsi H, Villani DA, Soniwala S, Dar QA, Schott EM, Gill SR, Zuscik MJ. The gut microbiome-joint connection: implications in osteoarthritis. *Curr Opin Rheumatol.* 2020 Jan;32(1):92-101. PMID: 31724973; PMCID: PMC6903327.

Mobasheri A, Mahmoudian A, Kalvaityte U, Uzielien I, Larder CE, Iskandar MM, Kubow S, Hamdan PC, de Almeida CS, Favazzo LJ, van Loon LJC, Emans PJ, Plapler PG, Zuscik MJ. A white paper on collagen hydrolyzates and ultrahydrolyzates: Potential Supplements to Support Joint Health in Osteoarthritis?. *Curr Rheum Rep*, In Press. (Appendix 3)

b. Books or other non-periodical, one-time publications

Nothing to report

c. Other publications, conference papers and presentations:

Wu YH, Landgrave SH, Hendsi H, Favazzo LJ, Villani DA, Schroeder W, Thomas SM, Payne KA, Prawitt J, Gill SR, Zuscik MJ. Dietary supplementation with hydrolyzed hyaline cartilage mitigates posttraumatic

osteoarthritis: Potential role of shifts in the gut microbiome. American Society for Bone and Mineral Research annual meeting, September 11-15, 2020.

Zuscik MJ. From Gut to OA. Osteoarthritis Research Society International, OARSI Hour entitled “The gut microbiome and OA”. Virtual Live Presentation, August 19, 2020. (This award was acknowledged)

Zuscik MJ. Thinking outside the joint: Can gut interventions support disease modification in OA?. 6th Annual Vail Scientific Summit, Steadman Philippon Research Institute, August 21, 2021. (This award was acknowledged)

- Website(s) or other internet site(s)

Nothing to report

- Technologies or techniques

See below new claims that support pre/pro-biotic interventions as a technology to address PTOA.

- Inventions, patent applications, and/or licenses

New Allowed Claims, U.S. Patent Application Serial No. 16/489,890, Amended June 3, 2021 (Appendix 4).

- Other products

Nothing to report

7. Participants & Other Collaborating Organizations

- What individuals have worked on the project?

University of Colorado School of Medicine (Zuscik Partnering PI)

Name:	Michael Zuscik PhD
Project role:	Partnering PI
Researcher identifier:	0000-0003-0461-8708 (ORCID)
Nearest person month worked:	3
Contribution to project:	Contribution to design and planning of all aspects of the project
Funding support:	

Name:	Lisa Brenner PhD
Project role:	Co-I
Researcher identifier:	Not available
Nearest person month worked:	0.5

Contribution to project:	IRB development and planning for fecal collection from humans
Funding support:	

Name:	Honey Hendesi MD PhD
Project role:	Post-doc
Researcher identifier:	Not available
Nearest person month worked:	6
Contribution to project:	Contribution to design, planning and execution of all aspects of the project
Funding support:	

Name:	David Villani
Project role:	Graduate student
Researcher identifier:	Not available
Nearest person month worked:	12
Contribution to project:	Contribution to design, planning and execution of all aspects of the project
Funding support:	

Name:	Kelly Stearns-Yoder
Project role:	Clinical Coordinator
Researcher identifier:	Not available
Nearest person month worked:	0.6
Contribution to project:	IRB development
Funding support:	

Name:	Jake Guzzetti
Project role:	Clinical Coordinator
Researcher identifier:	Not available
Nearest person month worked:	1.8
Contribution to project:	IRB development
Funding support:	

University of Rochester School of Medicine and Dentistry (Gill Partnering PI)

Name:	Steven Gill PhD
Project role:	Partnering PI
Researcher identifier:	0000-0002-2408-1373 (ORCID)

Nearest person month worked:	3
Contribution to project:	Contribution to design, planning and execution of all aspects of the project, particularly as related to microbiome analysis and microbiology work.
Funding support:	

Name:	Ann Gill MS
Project role:	Senior technical associate
Researcher identifier:	Not available
Nearest person month worked:	6
Contribution to project:	Contribution to microbiome analysis and microbiology work.
Funding support:	

Name:	Cal Palumbo MS
Project role:	Bioinformatician and Data Analyst
Researcher identifier:	Not available
Nearest person month worked:	2.4
Contribution to project:	Contribution to microbiome analysis.
Funding support:	

- Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Yes, new awards listed below:

Zuscik

1 R01AR078414-01 (Zuscik, Gill) 04/01/2021 – 03/31/2026 3.00 calendar

National Institutes of Health/NIAMS

Role: MPI, Contact PI

Studies on gut microbiome-joint connections in arthritis

This project aims to 1) definitively establish that a pro-inflammatory dysbiotic gut microbiome is causal in the osteoarthritis of obesity, and 2) demonstrate that correction of this dysbiosis using strategies to expand *B. pseudolongum* will decelerate the progression of osteoarthritis in the obese context.

NO OVERLAP (studies are focused on OBESITY-INDUCED OA)

ABNexus (MPI: Bryant, S & Payne, K)

01/01/2021 – 12/31/2021 0.6 calendar

University of Colorado

(TDC)

Role: Co-I

Biophysical Cues Governing Growth Plate Organization: A Computational & Experimental Approach

This project will develop the first growth plate organoid with the ability to recapitulate the columnar organization of cells, a key structural determinant that is required for normal growth in children. This organoid will allow for deeper study of bone growth and genetic diseases affecting growth plate development and will have regenerative medicine relevance in children with growth plate injuries and growth disorders.

NO OVERLAP

Contract Agreement 203066 (PI: Zuscik)

06/11/2020 – 12/31/2021 0.6 calendar

Radius Health

(TDC)

Role: PI

Impact of Abaloparatide on Murine Posttraumatic Osteoarthritis

Preclinical experiments in a mouse model of posttraumatic osteoarthritis will be performed to study the impact of PTH1R receptor agonist abaloparatide on cartilage structure and disease progression. These experiments are the preclinical proof of concept studies necessary to establish rationale for pursuit of a phase 2 clinical trial in human OA.

NO OVERLAP

Contract Agreement 200709 (PI: Zuscik)

01/01/2021 – 06/30/2022 1.2 calendar
(TDC)

Rousselot BVBA

Role: PI

Investigation of the joint protective effect of hydrolyzed hyaline cartilage (hHc)

This phase II, double blind, placebo controlled clinical trial will determine if hHC, via prebiotic effects playing out in the gut microbiome, is chondroprotective in early-mid stage osteoarthritis in humans.

NO OVERLAP (this is a HUMAN CLINICAL TRIAL testing hCol1 as an intervention)

Grubstake 03-2021 (PI: Zuscik)

01/01/2021 – 12/31/2023 0.6

calendar

Gates Regenerative Medicine Center

(TDC)

Role: PI

Abaloparatide as the first chondroregenerative therapy for osteoarthritis

This project focuses on study of the role of the chondrocyte in the joint preserving effects of abaloparatide, along with in vitro experiments to study the effects of abaloparatide in human articular chondrocytes.

NO OVERLAP

PENDING

NSF 2124693 [Awarded] (Payne)

12/01/2021 – 11/30/2025 0.6 calendar

National Science Foundation

Role: Co-PI

Collaborative Research: RECODE: Organoid model of growth plate development

This research will provide fundamental insight into the mechanisms that govern stem cell differentiation and organization into a mature, functional growth plate organoid.

NO OVERLAP

Gill

NEW CURRENT

1 R01AR078414-01 (Zuscik, Gill)

04/01/2021-03/31/2026 3.00 calendar

National Institutes of Health/NIAMS

Role: MPI

Studies on gut microbiome-joint connections in arthritis

This project aims to 1) definitively establish that a pro-inflammatory dysbiotic gut microbiome is causal in the osteoarthritis of obesity, and 2) demonstrate that correction of this dysbiosis using strategies to expand *B. pseudolongum* will decelerate the progression of osteoarthritis in the obese context.

NO OVERLAP (studies are focused on OBESITY-INDUCED OA)

UG3/UH3 DE030434-01 (Kopycka-Kedzierawski)

04/01/2021-03/31/2027 1.80 calendar

National Institutes of Health/NIDCR

Role: Co-I

Povidone Iodine Efficacy Study

The goal of this project is to determine the efficacy of Povidone Iodine as a therapeutic for treatment of early childhood caries in children.

NO OVERLAP

NEW PENDING

R01 MH125103 (MPI: Gill/Scheible/O'Connor)

04/01/2022-03/31/2027 3.0 calendar

National Institutes of Health/NIMH

Role: MPI, Contact PI

Neurobiological and Neurocognitive Consequences of Diverse Microbiome Functional Trajectories

The goals of this project are to elucidate the prenatal determinants of initial gut microbiome seeding in human newborns, and to measure the impact of postnatal microbiome development and timing, location and concentration of microbiome-derived biochemical messengers on human neurodevelopment through age 4 years.

NO OVERLAP

R01 DE031025 (MPI: Xiao/Gill)

04/01/2022-03/31/2027

3.0 calendar

National Institutes of Health/NIDCR

Role: MPI

Understanding biological factors underlying early childhood caries disparity from the oral microbiome in early infancy

The goals of this project are to understand the biological factors underlying ECC disparity with a focus on the oral microbiome in early infancy, develop ECC prediction models for underserved children, and generate innovative strategies for ECC prevention by promoting a healthy oral microbiome in early infancy.

NO OVERLAP

- What other organizations were involved as partners?

- a. Organization Name:
Rousselot BVBA
- b. Location of Organization:
Gent, Belgium
- c. Partner's Contribution to the Project:
Other: Study material, hydrolyzed hyaline cartilage

8. Special Reporting Requirements

- Collaborative Award

This is a collaborative award. Partnering PIs Michael Zuscik PhD and Steven Gill PhD are located at the University of Colorado and University of Rochester, respectively. This report has denoted which aspects of the project have been completed at each site, so both partnering PIs will be submitting this same document.

- Quad Charts

Not applicable

Dietary Supplementation with Hydrolyzed Hyaline Cartilage Mitigates Posttraumatic Osteoarthritis: Potential Role of Shifts in Gut Microbiome



Y.H. Andrew Wu¹, Samantha H. Landgrave^{1,2}, Honey Hendesi¹, Lacey J. Favazzo¹, David A. Villani^{1,2}, William Schroeder¹, Stacey M. Thomas¹, Karin A. Payne^{1,2}, Janne Prawitt³, Michael J. Zuscik^{1,2}

1. Department of Orthopedics, Anschutz Medical Campus, Aurora, Colorado
 2. Cell Biology, Stems Cells and Development Program, Anschutz Medical Campus, University of Colorado, Aurora, Colorado
 3. Rousselot BVBA, Gent, Belgium

INTRODUCTION


Osteoarthritis (OA) is a leading cause of disability globally. Symptom palliation is the only option for treatment as there is no available disease-modifying therapy. It has recently been suggested that changes in the gut microbiome dysbiosis can influence OA progression; in fact, the chondroprotective effects of various nutraceuticals, including dietary supplements comprised of cartilage components, may be due to their ability to shift the gut microbiome composition^{1,2}.

AIM

One supplement in particular, known as hydrolyzed hyaline cartilage (hHC), has anecdotally been identified as joint protective. However, the exact mechanism of this protection and the potential involvement of the gut microbiome is yet to be explored. This study aimed to investigate the basis for joint protection conferred by hHC in OA.

METHOD

- Posttraumatic OA (PTOA) was surgically induced via destabilization of the medial meniscus (DMM) in mice consuming a defined diet from OpenSource (D1245H)
- Injured mice were provided a daily oral supplement of hHC (0.62mg/gm body weight) or vehicle, beginning 2 weeks prior to injury
- Three- and 12-weeks post-injury, knee joints were harvested, fixed, embedded in paraffin and cut sections were stained with Safranin O
- Histomorphometry analyses were performed to measure the area of femur and tibial cartilages
- TNF immunohistochemistry was performed to study joint inflammation and TUNEL staining was performed to assess chondrocyte apoptosis
- Fecal material was also collected to support analysis of the gut microbiome via 16S rDNA sequencing



RESULTS

Histomorphometry revealed that hHC-supplemented mice had more tibial and femoral uncalcified cartilage at both 3- and 12-week post-injury (Figure 1a and b). These results may be related to suppression of inflammation in the hHC cohort, which displayed a trend toward reduced synovial chondrocyte apoptosis in hHC-supplemented mice (Figure 3), suggesting a potential mechanistic association. hHC-supplemented mice displayed significant shifts in the gut microbiome that included loss of proinflammatory species and family members, particularly the species *rc4-4* (Figure 4).




Figure 4: hHC-supplemented mice displayed significant shifts in the gut microbiome that included loss of the proinflammatory species *rc4-4*





Figure 1a: Cartilage area was evaluated using Osteomeasure System to determine the tibial/femoral uncalcified cartilage area and the total Safranin O-positive chondrocytes in the tibial and femoral cartilage at 12 weeks post-DMM




Figure 2: Array of representative 200x TNF immunohistochemistry study, focusing at the synovial located at the junction between tibial plateau (T) and the meniscus (M). Red arrows represent TNF expression positivity





Figure 3: 200x Sagittal sections from the medial compartment of Sham and DMM joints 3 weeks and 12 weeks post-DMM were prepared and apoptotic nuclei (green) were identified via TUNEL staining.

CONCLUSIONS

Findings suggest that oral dietary supplementation with hHC confers joint protective effects in PTOA as well as parallel alterations in the gut microbiome. This sets the stage for follow-on study of the potential mechanistic link between the microbial shifts induced by hHC and its ability to support chondroprotection.

REFERENCES

1. Schott EM, Farnsworth CW, Grier A, Lillis JA, Soniwal S, Dabourian GH, et al. Targeting the gut microbiome to treat the osteoarthritis of obesity. JCI Insight. 2018;3(6).
2. Favazzo LJ, Hendesi H, Villani DA, Soniwal S, Dar QA, Schott EM, et al. The gut microbiome-joint connection: implications in osteoarthritis. Curr Opin Rheumatol. 2020;32(1):92-101.

ACKNOWLEDGEMENTS

DOD IIRA W81XWH1910807; Rousselot BVBA

CONTACT INFORMATION

Professor Michael Zuscik
 Email: Michael.Zuscik@colorado.edu

10. Appendix 2: Early microbiome analysis from the mouse PTOA cohort




Figure 1. Mice with DMM have a different gut microbiome than mice without DMM. **(A)** Principle coordinate analysis shows that mice that received DMM surgery cluster distinctly from mice that received sham surgery. **(B)** Individual taxa are significantly different in mice that received DMM surgery compared to sham surgery. Unpaired student's t test * $p < 0.05$, ** $p < 0.01$



A White Paper on Collagen Hydrolyzates and Ultrahydrolyzates: Potential Supplements to Support Joint Health in Osteoarthritis?

Ali Mobasheri^{1,2,3,4,5} · Armaghan Mahmoudian⁶ · Ursule Kalvaityte² · Ilona Uzieliene² · Christina E. Larder⁷ · Michèle M. Iskandar⁷ · Stan Kubow⁷ · Paulo Cesar Hamdan⁸ · Cyro Scala de Almeida Jr⁹ · Lacey J. Favazzo¹⁰ · Luc J.C. van Loon¹¹ · Pieter J. Emans¹² · Pérola G. Plapler¹³ · Michael J. Zuscik^{10,13}

Accepted: 30 June 2021

© The Author(s) 2021

Abstract

Purpose of Review Osteoarthritis (OA) is the most common forms of arthritis in the general population, accounting for more pain and functional disability than any other musculoskeletal disease. There are currently no approved disease modifying drugs for OA. In the absence of effective pharmacotherapy, many patients with OA turn to nutritional supplements and nutraceuticals, including collagen derivatives. Collagen hydrolyzates and ultrahydrolyzates are terms used to describe collagens that have been broken down into small peptides and amino acids in the presence of collagenases and high pressure.

Recent Findings This article reviews the relevant literature and serves as a White Paper on collagen hydrolyzates and ultrahydrolyzates as emerging supplements often advertised to support joint health in OA. Collagen hydrolyzates have demonstrated some evidence of efficacy in a handful of small scale clinical trials, but their ability to treat and reverse advanced joint disease remains highly speculative, as is the case for other nutritional supplements.

Summary The aim of this White Paper is to stimulate research and development of collagen-based supplements for patients with OA and other musculoskeletal diseases at academic and industrial levels. This White Paper does not make any treatment

Ursule Kalvaityte, Ilona Uzieliene, Christina E. Larder and Michèle M. Iskandar contributed equally to this work.

This article is part of the Topical Collection on *Complementary and Alternative Medicine*

✉ Ali Mobasheri
ali.mobasheri@oulu.fi

✉ Michael J. Zuscik
michael.zuscik@cuanschutz.edu

Armaghan Mahmoudian
armaghan.mahmoudian@gmail.com

Ursule Kalvaityte
ursule.kalvaityte@imcentras.lt

Ilona Uzieliene
ilona.uzieliene@imcentras.lt

Christina E. Larder
christina.larder@mail.mcgill.ca

Michèle M. Iskandar
michele.iskandar@mcgill.ca

Stan Kubow
stan.kubow@mcgill.ca

Paulo Cesar Hamdan
paulohamdan@yahoo.com.br

Cyro Scala de Almeida, Jr
cyroscala@gmail.com

Lacey J. Favazzo
lacey.favazzo@cuanschutz.edu

Luc J.C. van Loon
l.vanloon@maastrichtuniversity.nl

Pieter J. Emans
p.emans@mumc.nl

Pérola G. Plapler
perolagp@yahoo.com

Extended author information available on the last page of the article

recommendations for OA patients in the clinical context, but simply aims to highlight opportunities for scientific innovation and interdisciplinary collaboration, which are crucial for the development of novel products and nutritional interventions based on the best available and published evidence.

Keywords Joint health · Osteoarthritis · Nutritional supplement · Nutraceutical · Denatured collagen · Collagen hydrolyzate · Collagen ultra-hydrolyzate

Introduction

OA is believed to impact more than 300 million people worldwide [1]. It is estimated that a “tsunami” of new OA cases will hit countries with a much larger aging population in the developed world by the year 2050 [2]. However, these numbers provided by epidemiological studies are likely an underestimation, and the true burden of OA is likely to be much higher as accurate data are not available for sub-Saharan Africa, Central America, or South America. A recent commentary published in *The Lancet* has proposed that the incidence of OA is much higher, estimated at around 7% of the global population; this means that more than 500 million people worldwide have OA [3].

OA is an especially problematic disease as there are currently no effective pharmacological treatments and no disease modifying OA drugs (DMOADs). There is some correlation between published treatment guidelines overall but there is no clear consensus in any of the treatment guidelines regarding nutraceuticals and supplements. Furthermore, the guidelines and recommendations for the management of OA are difficult to follow for most healthcare professionals and patients, often leaving them dissatisfied and confused. Patients also remain dissatisfied with the currently approved pharmacological interventions; in the absence of DMOADs, they resort to using nutritional supplements and nutraceuticals. Recent guidelines have been published by the American College of Rheumatology (ACR), Arthritis Foundation (AF), the European League Against Rheumatism (EULAR), the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and Osteoarthritis Research Society International (OARSI) [4–6]. The recent ACR/AF 2020 OA treatment guidelines only focus on management options that are available in the USA and are restricted to pharmacologic therapies and agents that are available in pharmaceutical-grade formulations, thus eliminating consideration for most nutraceuticals according to ACR and FDA criteria [7, 8]. The OARSI 2019 treatment guidelines do not include nutraceutical products because the OARSI expert group has strongly

argued that the formulations have not yet been standardized [9]. However, the ESCEO 2019 Treatment Guidelines Working Group continues to advocate for the use “pharmaceutical grade” or “prescription grade” crystalline glucosamine sulfate (GS) and chondroitin sulfate (CS) as step 1 in pharmacological treatment. ESCEO argues that the formulations for GS and CS in Europe are standardized as “pharmaceutical grade” or “prescription grade” [10].

The lack of consensus on supplements creates major challenges for the research community, healthcare professionals, and OA patients, especially those who continue to use supplements combined with over-the-counter (OTC) medications [11]. Individuals with OA using supplements also report using OTC products in combination with prescription products and the likelihood of using prescription products increases with the length of OA history [11]. This suggests that patients continue consuming supplements irrespective of what the treatment guidelines might state.

Another major challenge in the use of nutritional supplements in OA is the use of terminology; vocabulary used to describe supplements is highly variable. Some papers refer to these products as food supplements while others refer to them as nutritional supplements or nutraceuticals. The literature often refers to them as complementary and alternative medicines, and there are papers that refer to plant-derived supplements as botanical and herbal supplements. The phrases “food supplements” and “nutraceuticals” have been used interchangeably since both types of supplements claim to benefit health. It is important to define key terms that have been accepted by regulatory agencies (Table 1).

Nutraceuticals are derived from a food or part of a food that is aimed toward disease prevention or treatment, whereas food supplements are generally referred to as single substances used either alone or in a mixture to support micronutrient needs [12]. In this White Paper, we discuss, among other agents, the potential for using collagen or collagen hydrolyzates as novel and innovative nutraceuticals to support joint health and provide prophylactic treatment for people with OA.

Table 1 Definitions of nutritional supplements and nutraceuticals

Term	Source	Definition
Food supplement	United States Government Office, 1994	A product (other than tobacco) in the form of a capsule, powder, softgel, or gelcap intended to supplement the diet to enhance health that bears or contains one or more of the following dietary ingredients: a vitamin, mineral, amino acid, or other botanical or dietary substance. United States Food and Drug Administration (FDA). Dietary Supplement Health and Education Act (DSHEA). U.S. Department of Health and Human Services. 1994. United States. Public Law 103–417. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
Food supplement	European Union (EU) and European Commission (EC), 2002	Food product whose purpose is to supplement the normal diet and which consists of a concentrated source of nutrients or other substances with nutritional or physiological effects, single or in combination, marketed in dosed formulations, such as capsules, tablets or pills, designed to be taken in small individual quantities measured. EU Directive 2002/46/EC https://ec.europa.eu/food/safety/labelling_nutrition/supplements_en https://eur-lex.europa.eu/eli/dir/2002/46/oj
Nutraceuticals	Brower V., 1998	Any substance that is a food or a part of a food and is able to induce medical and health benefits, including the prevention and treatment of disease [13]
Nutraceuticals	European Nutraceutical Association (ENA), 2016	Nutritional products that provide health and medical benefits, including the prevention and treatment of disease [14]

Opportunities for Management of OA with Nutraceuticals

Nutraceuticals and natural products for OA are sold and marketed for their antioxidative and anti-inflammatory

properties, with many manufacturers claiming they possess therapeutic, anabolic, and regenerative effects [15–18]. Recently published data from a small number of studies of herbal and botanical nutraceuticals developed from natural products have provided promising efficacy data compared to placebo comparators, but their potential for treating OA requires further confirmation in larger clinical trials [19, 20].

Currently, nutraceuticals constitute a wide variety of natural product extracts generated from different plants and animals, as well as their derived active ingredients [4]. Although nutraceuticals have gained enormous popularity in patient-driven inflammatory disease management, detailed mechanistic evidence of their efficacy in OA is still lacking [21].


Collagen Supplements

Non-hydrolyzed Collagen

These nutritional supplements are often a by-product from the food industry. Collagen supplements are rich in amino acids such as glycine, proline, and hydroxyproline; all of which play important roles in the building of joint cartilage and may also have anti-inflammatory and antioxidant effects, and have been speculated to act as signaling molecules [5]. While a seminal study published in *Science* in 1993 revealed efficacy of oral type II collagen supplementation in reducing joint swelling in RA [6], trials into the role of collagen supplementation in treating OA have demonstrated inconsistent results [19]. There have been several reported analgesic and anti-inflammatory effects of collagen in unpublished clinical trials, but according to recently published systematic and narrative reviews, these have not been reproduced across studies [19, 20]. Further trials with improved study designs are therefore needed to evaluate their proposed nutraceutical potential (Fig. 1).

Nutraceutical supplements derived from collagen can be made from beef, pork, or fish bones and skins, which undergo processing to increase the bioavailability of their amino acids and/or peptides; the enzymatic hydrolysis of collagens enhances the postprandial absorption of its processed components [22]. Processed and pre-digested collagen products are called collagen hydrolyzates CHs and are sold in the form of collagen capsules at pharmacies and health food suppliers. Different processing and manufacturing methods to make collagen hydrolyzates can yield different products, with differences in amino acid content and peptide sequences that vary in molecular weight (MW). Lower MW peptides may be more easily absorbed in the small intestine, increasing the likelihood of delivery to other areas in the body such as joints (Fig. 2).


Fig. 1 Schematic illustration of the ultrahydrolyzed collagen concept



Type II collagen is the most abundant protein found in articular cartilage and intervertebral discs. Because type II collagen is the main protein in cartilage, there have been suggestions that oral collagen supplementation may help to

support cartilage repair. However, definitive proof for this is still lacking. Different formulations of collagen have been developed based on the degree of hydrolysis, the most prevalent being undenatured collagen and hydrolyzed collagen.

Fig. 2 Proposed concept for the delivery of collagen-derived peptides to the synovial joint. Possible mechanism for immunometabolic and phenotypic reprogramming of macrophages by peptides derived from ultrahydrolyzed and hydrolyzed collagen



Undenatured Collagen

Undenatured type II Collagen (UC-II) is a patented agent that is often derived from chicken cartilage and has been used in various clinical trials in humans and companion animals, including dogs and horses [23–27]. Undenatured collagen is biochemically modified (glycosylated), has a good safety profile [28], and has been speculated, but not proven, to possess immunomodulatory properties. To what extent undenatured collagen is digested and absorbed following ingestion *in vivo* in humans remains to be assessed, but it has been speculated that potential bioactive peptides may be preserved and absorbed as free amino acids, especially glycine and proline. These amino acids represent quantitatively important precursors for the synthesis of cartilage extracellular matrix (ECM) macromolecules.

Whether UC-II, glycosylated or biochemically modified by some other means, has functional benefits beyond the provision of relevant amino acids as precursors for *de novo* collagen protein synthesis will be an important area of research and innovation and exemplifies an opportunity for further evidence-based product development by consumer health companies. Work in this space will need to systematically correlate efficacy at reducing symptoms with mechanism of action, with adaptive trial designs and with many open questions remaining on the ability of UC-II to exert direct effects on cartilage metabolism in joints.

Hydrolyzed Collagen

Hydrolyzed collagen is a form of collagen that is also referred to as collagen hydrolyzate. Collagen hydrolyzate and gelatin may be the same in terms of amino acid composition, but they possess different chemical properties. Collagen is a native protein molecule with a molecular weight of ~300 kDa [29]; and collagen hydrolyzates are processed intensively to break up the large collagen molecules into smaller fragments to increase absorption (Fig. 1).

To produce hydrolyzed collagen, native collagen undergoes denaturation followed by a hydrolysis process, resulting in very low molecular mass (3–6 kDa) collagen peptides, compared to native collagen size (285–300 kDa) [29]. Different processing and post-processing methods to make collagen hydrolyzates can yield vastly different products, creating different collagen peptide sequences and molecular weights. These differences can potentially impact biological function in terms of regulating joint inflammation and effect on subchondral bone. Furthermore, lower molecular weight collagen peptides may be more easily absorbed in the small intestine, theoretically increasing the likelihood of being delivered to other areas in the body including joints. The resistance of collagen peptides to hydrolysis and digestion is primarily based on amino acid composition. In that regard,

peptides with the amino acid proline or hydroxyproline are not readily hydrolyzed, or digested by the gastrointestinal system which may allow them to be absorbed in the small intestine. In support, peptides such as Pro-Hyp and Pro-Hyp-Gly, derived from the repeating motif Pro-Hyp-Gly, have been reported to circulate in the blood up to 4 h after oral collagen and gelatin ingestion [30, 31]. Thus far, there are no published studies that have conducted a quantitative assessment of the actual quantity of collagen derived peptides that are absorbed in the gastrointestinal tract and/or released in the circulation.

A number of clinical trials have been conducted concerning oral supplementation of collagen and its derivatives, undenatured and hydrolyzed collagen. All have shown to be safe and tolerable for the patient, causing no or only mild adverse effects to some patients [32, 33]. One of the concerns regarding oral collagen supplementation is associated with oral tolerance. Oral tolerance is the ability of orally administered antigen to suppress or minimize the immune response, and has been used to manage the occurrence of immunogenicity in other disease management [34–39].

As for oral tolerance associated with collagen, the response relies on structural properties of the collagen derivative because only specific epitopes found in an intact helix structure of the undenatured collagen are recognized by the immune system. The epitopes interact with gut-associated lymphoid tissue (GALT) and result in reduction of systemic T cell attack on the cartilage as well as reduced joint inflammation and cartilage damage [40–42]. This suggests that if taken orally, hydrolyzed collagen is digested and broken down into small peptides and amino acids, thus potentially eliminating its immunomodulatory properties.

Due to its lower molecular weight, hydrolyzed collagen has been proposed to have higher bioavailability and solubility, and thus better absorption from the small intestine compared to undenatured collagen [22, 29]. Absorption of orally administered hydrolyzed collagen has been evaluated by studying vascular-perfused rat intestine *in situ*. The results implied that the breakdown products of hydrolyzed collagen digestion can be absorbed as small peptides [43]. Defining and understanding the difference between collagen products, collagen hydrolyzates, and ultrahydrolyzed collagen can be difficult, confusing, and remains unclear in the literature.

Studies evaluating collagen digestion and amino acid and/or peptide absorption *in vivo* in humans are required to address the proposed differences in the postprandial bioavailability of collagen-derived amino acids and peptides.

In vitro studies have been used to suggest that collagen derived peptides may: (a) potentially accumulate in cartilage (if given in sufficiently high doses); (b) stimulate chondrocytes to synthesize ECM macromolecules *in vitro*; and (c) increase osteoblast activity as well as decrease osteoclastic activity [44, 45, 46–48]. However, whether such peptides are actually absorbed and released in an *in vivo* setting

remains highly speculative. Further studies are required to identify such absorbable bioactive peptides derived from (hydrolyzed) collagen digestion, as the impact of digestion and first pass metabolism on the generation of bioactive peptides from collagen hydrolyzates remains to be investigated. Such research may help to identify peptides and amino acids contributing to the proposed antioxidant and anti-inflammatory properties of collagen hydrolyzate supplementation. In this regard, preclinical research using innovative simulated digestion models in combination with relevant cell/tissue cultures can become an innovative higher throughput platform for investigating new collagen hydrolyzate formulations.

The early papers that appeared on collagen hydrolyzates reported efficacy in the preclinical context (beneficial effects on cartilage metabolism) and improvements in joint pain in the clinical context. Bello and Oesser reviewed the available literature on collagen supplements without date limits and published their results in 2006 [44]. In addition to published papers, they included abstracts presented at scientific congresses and articles published in German medical journals [44]. They reported that orally administered collagen hydrolyzate end products can be taken up by the intestine and accumulate in cartilage [44]. They also proposed that collagen hydrolyzate ingestion can stimulate the synthesis of ECM macromolecules. Bello and Oesser identified four open-label and three double-blind studies. Although some of these clinical trials were of very low quality, they reported that collagen hydrolyzates are safe and may improve pain and function in men and women with OA and other arthritic conditions. It is important to note, however, that the authors included other joint diseases in their review and their focus was not exclusively on OA.

In a trial investigating hydrolyzed collagen and green tea extract supplementation in dogs, the combined treatment decreased indicators of pain in dogs that received the combination product for 3 months. However, the biomarkers selected for evaluation of the effects of supplementation (Coll2-1 and Coll2-1 NO2) were unaffected [49].

An equine study from Utrecht University examined the effect of supplementation with collagen hydrolyzates and a multi-ingredient supplement for 60 days on experimentally induced acute synovitis in horses [50]. Synovitis was induced in the right intercarpal joint by intra-articular injection of 0.5 ng lipopolysaccharide (LPS) of *Escherichia coli*. Although supplementation with collagen hydrolyzates and the combination product showed anti-inflammatory effects in this validated synovitis model and prostaglandin E₂ (PGE₂) levels were reduced compared with placebo, no statistical differences were seen with respect to interleukin 6 (IL-6), glycosaminoglycans (GAGs), the biomarker CPII, or matrix metalloproteinases (MMPs) among treatment groups.

A supplement called PETAGILE, which provides collagen peptides, was orally administered to horses with mild or moderate OA for 3 months with daily doses of 25 g and 50 g. A weekly questionnaire to horse owners was provided in order to follow the progress of horse behavior and willingness to run. All 28 horses, (16 received 25 g/day and 12 received 50 g/day of PENTAGILE), improved their mobility and showed increased willingness to run as compared to the placebo group. The higher dosage (50 g) supplementation was concluded to be more effective and promising enough to further test in longer term studies [51].

Clark and colleagues performed a 24-week clinical study on the use of collagen hydrolyzates as a dietary supplement in 147 healthy athletes with activity-related joint pain who were physically fit, active, and had no evidence of joint disease [52]. The study design involved 72 males and 75 females randomly assigned to two groups. The experimental group ($n = 73$) received 25 mL of a liquid formulation of 10 g of collagen hydrolyzates. The placebo group ($n = 74$) received 25 mL of liquid xanthan. The primary measured outcome was a change in the visual analog scales (assessed by a physician) from baseline during the study phase in relation to pain, mobility, and inflammation. The team investigated joint pain at rest and when walking, standing, carrying objects, and lifting. This was the first clinical trial that used a healthy population as a study group and showed improvement in joint discomfort and pain in the group given an oral supplement containing collagen hydrolyzates. Despite the small sample size and limitations of the study, the results suggested that athletes perceived a benefit from consuming collagen hydrolyzates [52].

A clinical study in 15 healthy male subjects was carried out to determine and compare the plasma concentrations of four representative amino acids from collagen (glycine, proline, hydroxyproline, and hydroxylysine) following a single administration of a fresh fermented milk product containing hydrolyzed collagen [53]. This was a single-center, randomized open crossover study. In a fasting state, the 15 healthy subjects randomly received a single dose of product 1 (10 g of collagen hydrolyzate in 100 mL of milk) or product 2 (10 g of collagen hydrolyzate dissolved in 100 mL of water). The study showed that consumption of milk containing collagen hydrolyzate increased the concentration of collagen-specific amino acids in plasma. This suggests that orally ingested collagen hydrolyzates might increase the plasma concentrations of collagen-derived amino acids that could potentially reach tissues in the synovial joint.

Another clinical trial used a randomized double-blind, controlled study design and recruited 250 subjects with primary knee OA to assess the efficacy of a collagen hydrolyzate supplementation on OA pain and function [54]. The patients were given 10 g collagen hydrolyzate daily for 6 months. The authors reported a significant improvement in knee joint

function and pain as assessed by visual analog scales as well as the the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscales. Subjects with the greatest joint deterioration, and with the lowest intake of meat protein in their diets, appeared to benefit the most. The study concluded that collagen hydrolyzates are safe and effective and warrant further consideration as a functional food ingredient [54].

McAlindon and colleagues performed biochemical and imaging studies to examine the effect of collagen supplementation in human patients with OA. They attempted to determine whether either of two MRI approaches, delayed gadolinium enhanced magnetic resonance imaging of cartilage (dGEMRIC), or T2 mapping, might detect short-term changes in knee cartilage among individuals taking a formulation of collagen hydrolyzates. Their early results suggest that the dGEMRIC MRI technique may be able to detect changes in proteoglycan content in knee cartilage in individuals taking collagen hydrolyzate after 24 weeks compared to placebo [55]. Only weak correlations were observed between changes in dGEMRIC and biochemical markers, suggesting that the study duration was insufficient to detect measurable changes in biomarkers or that the biomarkers they selected were insufficiently sensitive and discriminatory. They found a positive effect of collagen hydrolyzates on cartilage morphology in patients with knee OA in their interventional OA study ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00536302): NCT00536302) [56]. However, they could not identify any consistent correlations in changes in collagen and proteoglycan biomarkers PIIANP and CS846 with changes of the dGEMRIC scores in patients who had received oral collagen hydrolyzates. An important weakness of this study was that the authors were looking for short-term changes which are difficult to detect, even after 48 weeks of oral treatment with collagen hydrolyzates. Although the study was time limited, the dGEMRIC score increased in the medial and lateral tibial regions of the knee joint in participants who were given collagen hydrolyzate compared to placebo.

A systematic review published in 2012 examined the evidence on the symptomatic and chondroprotective effects of collagen derivatives in OA. They reported that there is insufficient evidence to recommend the generalized use of collagen hydrolyzates in daily practice for the treatment of patients with OA [57]. They proposed that the overall quality of evidence was moderate to very poor and recommended more independent and high-quality studies to assess the proposed therapeutic effects of collagen derivatives on OA. It is important to note that they did not include studies on only collagen hydrolyzates; they reviewed the evidence from eight different studies: six on collagen hydrolyzates, two on gelatin, and one on UC-II. As previously mentioned, processing of collagen and their hydrolyzates may result in formulations with differing peptide and amino acid profiles, which may affect patient outcome.

A study published in 2017 examined the metabolic responses of human OA cartilage to biochemically characterized and fractionated collagen hydrolyzates [58]. It compared three different collagen hydrolyzates, two from fish (Peptan® F 5000, Peptan® F 2000) and one from pigs (Mobiforte®) and used biochemical (fluorescence) and biophysical techniques to characterize the products and their effects on human OA cartilage. It also determined the total number of peptides within each product and the peptides that were common between them. The investigators found that none of the three collagen hydrolyzates had the ability to positively modulate collagen biosynthesis in human knee cartilage explants. The authors noted that Peptan® F 2000 enhanced the activities of aggrecanases ADMATS4 and ADMATS5 *in vitro*. Furthermore, IL-6, MMP-1, -3, and -13 levels were elevated in explants that were treated with Mobiforte® and Peptan® F 5000. This study concluded that due to the heterogeneous peptide composition and disparate pharmacological effects among different collagen hydrolyzates, the effect of a particular preparation or processing cannot be extrapolated to other formulations.

Although there are promising collagen hydrolyzates, the literature has been riddled with poorly designed and executed studies decreasing the credibility of published material, even though positive effects have been demonstrated. For example, another poor study on fish collagen hydrolyzates was published by a group based in Thailand. This group claimed that collagen hydrolyzates can modulate cartilage metabolism [59]. Despite being published, the study was fundamentally flawed because the authors only looked at the effects of collagen hydrolyzates on cartilage explants. Knowing that the explant model is not always suitable for mechanistic studies of hydrolysate action, the results from this study should be interpreted with caution.

The most recent systematic review and meta-analysis of dietary and botanical supplements for OA looked at the evidence supporting the use of collagen hydrolyzates define and UC-II. Although their analysis showed significant improvements on pain, the quality of the published evidence was low and thus the clinical studies were deemed to have limited clinical impact [19]. The poor quality of published literature highlights the many knowledge gaps regarding collagen-based nutraceuticals, which require further high-powered and well-designed studies to propose evidence-based recommendations.

Emerging Research for Collagen Hydrolyzates

Research into collagen hydrolyzates has primarily focused on the benefits these products can have on joints, most often on cartilage tissue and subchondral bone. However, new and emerging fields of research have shown promise regarding

the additional health benefits these supplements can provide, due to their significant peptide and amino acid content and their general tolerability. A key new direction of the field is in the study of how collagen hydrolyzates support biological effects that are relevant in OA, with an emerging interest in how these supplements may modulate the gut microbiome by acting as potential pre- or pre-biotics (Fig. 3). The classical definition of a prebiotic is a food component that can change the activity or growth of the microorganisms found in the gastrointestinal tract. Changing the growth of different members of the microbiome can have implications in human health via modulation of the immune system and the production of metabolic byproducts of the gut flora that have biological action in the host.

The gut microbiome is the community of bacteria that resides in the gastrointestinal tract, includes the metabolic byproducts produced by the resident microbes. The amount of bacteria in and on the human body is far greater than the number of eukaryotic cells. The microbiome has a substantial impact on human health and clinical outcomes. The gut microbiome has been shown to affect multiple physiological pathways and disease states, including colon cancer, amyotrophic lateral sclerosis, RA, type 2 diabetes, metabolic syndrome (MetS), and Alzheimer’s disease. It is implicated in numerous inflammatory gastrointestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome, and it is known to influence various musculoskeletal diseases, OA, and osteoporosis (OP) [60–65]. A recent study by Schott et al. (2018) investigated the role of the gut microbiome in the context of obesity-associated OA [66]. Obesity was induced using a high-fat diet with mice that were

given a lean diet as a control. OA was induced using destabilization of the medial meniscus surgery. Mice were then supplemented either with oligofructose, a nondigestible prebiotic fiber, or cellulose, a control fiber. Results demonstrated that the gut microbiome of obese mice reverted to a state similar to that of the lean control mice after prebiotic supplementation. In the context of obesity, oligofructose supported the growth of key microflora, particularly *Bifidobacterium pseudolongum*. Furthermore, obese mice treated with oligofructose demonstrated cartilage preservation and an increased number of chondrocytes in the tibia and femur, as well as decreased OARSI scoring. No histological differences were observed in mice fed a low fat diet with or without prebiotic supplementation. Both systemic and synovial inflammation in obese mice were also reduced by oligofructose supplementation and the consequent changes in the microbiome. This report provided the first strong evidence for a link between the gut microbiome and OA [66]. This connection between the microbiome and joint health may also explain why some individuals respond to collagen hydrolyzate supplements while others do not. Interindividual differences in digestion and absorption rate of collagen hydrolyzate peptides and amino acids could also influence a patient’s response.

Perhaps the most intriguing explanation for interindividual differences in the digestion, uptake, and efficacy of collagen hydrolyzates and nutraceuticals in general is the substantial variability between the microbiomes of different individuals. Countless intrinsic and extrinsic factors, including diet, genetics, exercise level, diurnal rhythm, and even time of day contribute to different microbiome states within the niche of an individual gastrointestinal tract. Even when these factors are




Fig. 3 Possible mechanism of pre- or pre-biotic modulation by collagen derivatives

controlled, as in animal studies using defined diet, light cycle, and age matched controls, the specific microbiome fingerprint remains different between individual animals.

In a recent mouse study of gut microbiome, OA, and nutraceuticals, different microbiome profiles resulted from consumption of standard chow, high fat, and lean diets, and overlay of supplementation with UC-II or GS led to significant shifts in the constituent microbes [67]. Although the microbiome of each animal was distinct from all other animals, clear types were produced by the different supplements, with *Veillonella*, *Bifidobacteria*, and *Ruminococcus* genera contributing substantially to these profiles.

It is unsurprising that defined diet influences both the gut microbiome and OA outcomes in mice. What is intriguing is that dietary supplementation with nutraceuticals like CS causes shifts in the gut microbiome within the same control diet in mice [68]. In these animals, CS supplementation resulted in butyrogenic changes in the microbiome metabolism and lowered inflammatory LPS levels in circulation and caused a concomitant decrease in proinflammatory taxa and increase in anti-inflammatory taxa. Because OA has been shown to be a disease of inflammation, it is possible that the action of CS on OA is via the gut microbiome.

In human metabolism, degradation of CS is both variable and dictated in part by the innate gut microbiome. A 2016 study found that CS breakdown was caused by three different *Bacteroides* species in the gut found in all human participants. Even more interestingly, individuals in the study possessed at least two taxa that were not found in other study members that could also degrade CS [69]. It appears that the gut microbiome contributes to the metabolism of CS, within different population groups as well as between individual members of the groups; based on this it is not surprising that nutraceutical response is variable in the published literature.

In a study examining microbiome and OA changes caused by dietary supplementation with either GS or UC-II, a distinct microbiome profile was found for each group. A low Bacteroidetes/Firmicutes ratio has been associated with a pro-inflammatory state in both mice and humans [70, 71]. Compared to mice that were not given a nutraceutical, supplementation with either GS or UC-II resulted in a higher Bacteroidetes/Firmicutes ratio [67]. Individual operational taxonomic units (OTUs) were different in animals given nutraceuticals compared to animals given control fibers; furthermore, OTUs were significantly different depending on whether GS or UC-II was provided. Overall, the study found that supplementation with either GS or UC-II resulted in OTU changes that could be associated with lowered inflammatory states; ingestion of UC-II caused more changes in OTU abundances compared to GS, but there were nutraceutical specific microbiome changes in the case of GS and *Rikenellaceae*. Perhaps most crucially, dietary supplementation with either nutraceutical increased tibial total and uncalcified cartilage

area, as well as Safranin O chondrocytes, compared to the control fiber, in a post-traumatic OA (PTOA) model. Collectively, these data implicate the gut microbiome as a mediator of nutraceutical action on OA outcomes.

Because of the microbiome and gastrointestinal tract relevance to nutraceuticals and OA, future collagen and OA research needs to implement the latest gastrointestinal models; these need to be scalable, fast, and physiologically relevant. Initiatives to make these digestion models more affordable and accessible have started [72–74], FYI our article is now published which uses the dynamic GI model to assess CH microbial metabolites. Future use of computer a controlled dynamic digestion model inoculated with human fecal matter can be used to investigate the digestibility of collagen hydrolyzates and their effect on the microbiome. In such bioreactor models, the stomach, small intestine, and three colonic vessels (ascending, transverse, and descending) are continuously agitated, pH controlled, and the digesta are propelled along the simulated gut model using peristaltic pumps. As our understanding of the microbiome and its impacts on overall health and OA evolve, simulated gut model studies investigating supplements that are readily available to patients are required to determine both the beneficial and potentially deleterious effects these products may have on the gastrointestinal system and how they affect OA.

Gastrointestinal models provide a unique opportunity to test collagen hydrolyzate products, as well as other drugs. These models can be inoculated with different human gut microbiota, allowing the impact of nutraceuticals and newly developed drugs on the gastrointestinal tract to be investigated. These models could also utilize the microbiota of patients with varying degrees of OA, first to determine if the microbiome between OA patients at different stages are different, and then to investigate the impact of new treatments. This model could function as a pre-clinical tool where the safety and toxicity of new drugs and nutraceuticals can be determined.

Challenges of Research with Nutraceuticals

Regulations

Due to the “non-medical” origin of nutraceuticals, there is a lack of regulatory methods and proof of efficacy requirements in Europe and the USA. But like pharmaceutical products, nutraceuticals should require strict regulations and evidence-based research that confirm efficacy, safety, and benefits to the patient [14].

Measurement Control

OA is lacking an proper measurement–control system for an objective evaluation of pre-clinical changes potentially

indicating an important windows of treatment opportunity. Recognizing OA in the phase is increasingly accepted as being such a window of opportunity. MRI has the capacity to diagnose OA in this early phase and DMOADs developed by Merck and Novartis have used this imaging technique for the assessment of structural [75]. For DMOADs, both functional and structural outcomes are considered mandatory by the FDA. Next to MRI, biochemical markers measured in synovial fluid, but preferably non-invasively, from urine, or from plasma or serum may aid the timing, registries and database building followed by outcome measurement and algorithm building to support joint-preserving treatments for OA in the field of lifestyle/nutrition, pharmacological interventions, and joint-preserving surgery. Ideally, such a measurement-control system is species independent to translate the same outcome measures from animal studies to clinical implementation. In this light, developments in the area of high-field MRI, mass spectrometry, and a combination thereof, are highly promising.

Animal Studies

Animal studies are generally slow, costly and predictions of bio-availability do not always align with human clinical data owing due to species differences in intestinal permeability and metabolic activity [76, 77]. The bioavailability of food components is determined by first-pass metabolism, which involves absorption by enterocytes found in the gastrointestinal tract, followed by liver metabolism before entering the systemic circulation [78, 79]. Bioavailability studies of food components and pharmaceuticals using animal models have previously established poor correlation between rats and humans. Due to these species differences in intestinal permeability and metabolic activity, *in vitro* digestion and cell culture models, rather than animal models, are often used to assess the digestion profile and intestinal transport of orally administered food components or drugs. *In vitro* digestion models are often used to assess for nutrient digestion before first pass metabolism, as human trials are difficult and impractical for routine nutrient bioavailability assessments [80–82]. Previous and ongoing validation studies continue to support the use of *in vitro* digestion models for testing nutrient digestion, and for bioactive peptides, by comparing to *in vivo* results [82, 83]. One of the limitations of previous research on collagen products is that they have often used these products directly on tissues, such as cartilage, to determine their effects, but in a physiological context, these products first undergo digestion and first pass metabolism. Future research needs to consider more holistic and physiologically relevant approaches to validate mechanisms of action of collagen-based products for the treatment of OA.

Human studies

Human studies provide the most accurate and valuable outcomes, although there are still several limitations and study design choices which should be taken into consideration. One of these parameters is the choice of test and control groups, which should be distinguishable from one another, and the selection of either of these groups must be based on specific demographic and population variables. For example, as nutritional requirements differ according to a person's age, the target population of a nutraceutical should be focused on a specific age group. If the target population is the elderly, difficulties arise as it is challenging to identify all risk factors, comorbidities, and possible interactions, as well as to model a study according to all these aspects. The exposure to nutraceuticals and the interindividual variation of response are also crucial aspects, as well as the fact that nutraceuticals are subjected to intestinal bacterial metabolism which can generate active or inactive metabolites. Capping off the complexity are considerations around disease etiology. The OA syndrome is not driven by a single pathogenic mechanism, but rather can be initiated by various factors including age, obesity, genetics, and injury. Specific supplements may have efficacy in one context but not another, and so studies should consider information about likely initiators of degeneration. To understand the effects of a nutraceutical with these variables in mind, studies with large populations and elevated financial expense are necessary [84]. Other crucial features of a study to be considered are duration, timing, and budget.

The formulation in which a nutraceutical is manufactured can also have an impact related to the pharmacokinetics of the relevant bioactives in terms of absorption, distribution, metabolism, and excretion (ADME). The ADME can determine factors such as dose, half-life, and frequency of intake of the supplement that impact bioactivities. Formulation may not necessarily cause adverse effects or be harmful to therapeutic outcomes but could alter the absorption rate and efficacy of the nutraceutical. Formulation should be chosen according to the origin of the functional elements included in the preparation, its solubility, resistance to pH changes, and impact of shifts in the microbiota on permeability and stability of the nutraceutical. Novel Drug Delivery Systems (NDDS) compared to simple and widely used formulations offer advantages by enhancing stability, providing sustained release, and protecting the compound(s) from physical or chemical degradation [85].

Many challenges surround the evaluation of nutraceutical efficacy, safety, and regulations. As interest and consumer consumption increases, the lack of clear clinical evidence is still a limitation. To address this and ensure the best outcomes for consumers, a variety of complementary research approaches are needed. In that regard, *in vitro* studies can be used to provide proof of concept, for safety assessment, and

to help understand how a supplement might impact on structure and function. Appropriate animal models for OA can also aid in assessments of nutraceuticals in terms of potency, safety, and mechanisms of action. These studies can evaluate the impact of both acute and long-term nutraceutical supplementation and control for confounding variables such as genetics, sex, and background diet. In vitro and in vivo preclinical studies aid in the determination of relevant biomarkers, outcome measures, and the experimental design for human nutraceutical studies, which are crucial for validation. Clinical studies remain the most verifiable approach to evaluate how interindividual variabilities in gut microbiota and host response involving differing genetic, biochemical, and anatomical characteristics can impact the health promoting properties of nutraceuticals. It should be recognized, however, that the complexity of nutraceutical metabolism leads to a large variety of metabolites that make it unlikely to characterize all pertinent features of metabolic activity. Moreover, a wide variety of baseline lifestyle factors including nutritional status, and background dietary and exercise habits could lead to variable interindividual responses to nutraceutical supplementation.

Future Innovations in Nutraceuticals

By 2025, the collagen market is estimated to be valued at \$6.63 billion, and in this year alone, U.S. consumers are expected to spend around \$122 million on collagen products. The largest component will be cosmetic collagen, but a substantial portion of the emerging market will be collagen-based nutraceuticals for bones and joints. Patients with OA consume supplements along with OTC products [11]; they hope for readily available, new, and innovative nutraceuticals. There is an opportunity to develop combination nutraceuticals incorporating collagen ultra-hydrolyzates since supplements remain very appealing for many patients dissatisfied with current conventional drugs.

Conclusions

A growing body of work has accumulated to provide a scientific rationale for the use of oral collagen hydrolyzates to treat patients with OA. However, evidence for their clinical efficacy is lacking and mechanistic and targeted clinical research is required to determine if and how collagen hydrolyzates may help to improve joint health [86, 87]. We need to determine which OA phenotypes and subpopulations are the most appropriate for demonstrating the potential benefits of oral collagen supplements. Collagen hydrolyzates have demonstrated some evidence of efficacy in several small scale clinical trials, but more research is needed. Collagen hydrolyzates are likely to

have a much greater impact in patients with early OA compared to patients with advanced OA. Also, collagen hydrolyzates have the potential for use in a healthy population without OA, as a preventive and prophylactic measure. Collagen hydrolyzates are considered an attractive nutritional supplement for preventing bone and joint degeneration in early stages of OA, but their ability to treat and reverse advanced joint disease remains highly speculative. Novel and innovative research continues to be published on collagen hydrolyzates and links with the microbiome, but more work is needed. We advocate new interdisciplinary collaborative initiatives, at the academic and industrial level, to develop new products and critically evaluate the impact of collagen-based nutraceutical supplements for patients with OA and related osteoarticular disorders.

Abbreviations ACR, American College of Rheumatology; ADME, Absorption, distribution, metabolism, and excretion; AF, Arthritis Foundation; BCFA, Branched chain fatty acid; CS, Chondroitin Sulfate; dGEMRIC, delayed gadolinium enhanced magnetic resonance imaging of cartilage; DMOAD, Disease modifying OA drug; DSHEA, Dietary Supplement Health and Education Act; EC, European Commission; ECM, Extracellular matrix; ESCEO, European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases; EU, European Union; EULAR, European League Against Rheumatism; FDA, Food and Drug Administration of the United States; GAGs, Glycosaminoglycans; GS, Glucosamine sulfate; IL-6, Interleukin 6; IBD, Inflammatory bowel disease; LPS, Lipopolysaccharide; MetS, Metabolic syndrome; MMP, Matrix metalloproteinase; MRI, Magnetic resonance imaging; MW, Molecular weight; NDDS, Novel Drug Delivery Systems; OARSI, Osteoarthritis Research Society International; OA, Osteoarthritis; OP, Osteoporosis; OTC, Over the Counter; OTUs, Operational taxonomic units; PGE₂, Prostaglandin E₂; PTOA, Post-traumatic OA; RA, Rheumatoid arthritis; RMDs, Rheumatic and musculoskeletal diseases; SCFA, Short chain fatty acids; SYSADOAs, Symptomatic slow-acting drugs for OA; UC-II, Undenatured Type II Collagen; UN, United Nations; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index

Acknowledgements The authors wish to acknowledge Soraya Mobasheri at Klimaite and Klimaite graphic design (Berlin, Germany) for contributing figure 1.

Author Contribution Conceptualization: Ali Mobasheri; writing, review and editing: all authors. All authors made significant intellectual contributions to this manuscript.

Funding Open access funding provided by University of Oulu including Oulu University Hospital.

Declarations

Conflict of Interest Ali Mobasheri is Senior Advisor to the World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging and “Collaborateur Scientifique de l’Université de Liège” at the Université de Liège in Belgium. He has consulted for Genacol and Sterifarma, companies that produce and market collagen supplements. Ali Mobasheri has also consulted for Sanofi (Brazil), Pfizer Consumer Health, GSK Consumer Health, and Aché

(Aché Laboratórios Farmacêuticos), companies that have ongoing R&D activities in joint health supplements. Stan Kubow has received funding from Genacol for research in his laboratory at McGill University. Luc J.C. van Loon has received research grants, consulting fees, speaking honoraria, or a combination of these for research on the impact of exercise and nutrition on muscle metabolism, which include funding from companies that produce collagen such as Gelita and PB Leiner. A full overview on research funding is provided at: <https://www.maastrichtuniversity.nl/l.vanloon>

Michael J. Zuscik has received support from Rousselot Nutrition and Health, a company that has developed collagen peptide-based supplements.

The other authors declare that they have no competing interests. This paper was written by the authors within the scope of their academic and research positions. None of the other authors have any relationships that could be construed as biased or inappropriate. The public funding bodies that support our work were not involved in the data collection, analysis, and interpretation. The decision to submit the paper for publication was not influenced by any of the public funding bodies.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Kloppenburg M, Berenbaum F. Osteoarthritis year in review 2019: epidemiology and therapy. *Osteoarthr Cartil.* 2020;28:242–8.
2. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study. *Lancet.* 2018;392:1789–858.
3. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: a Lancet Commission. *Lancet.* 2020;396:1711–2.
4. Wang A, Leong DJ, Cardoso L, Sun HB. Nutraceuticals and osteoarthritis pain. *Pharmacol Ther.* 2018;187:167–79.
5. Paul C, Leser S, Oesser S. Significant amounts of functional collagen peptides can be incorporated in the diet while maintaining indispensable amino acid balance. *Nutrients.* 2019;11.
6. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, et al. Effects of oral administration of type II collagen on rheumatoid arthritis. *Science.* 1993;261:1727–30.
7. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Rheum.* 2019;72:220–33.
8. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. *Arthritis Care Res.* 2019;72:149–62.
9. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSÍ guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthr Cartil.* 2019;27:1578–89.
10. Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Semin Arthritis Rheum.* 2019;49:337–50.
11. ••Lane NE, Ivanova J, Emir B, Mobasher A, Jensen MG. Characterization of individuals with osteoarthritis in the United States and their use of prescription and over-the-counter supplements. *Maturitas.* 2021;145:24–30 **This study used data from the 2017 US National Health and Wellness Survey (NHWS) to show that individuals with OA in the United States use a combination of prescription drugs and over-the-counter supplements.**
12. Santini A, Novellino E. To nutraceuticals and back: rethinking a concept. *Foods.* 2017;6.
13. Brower V. Nutraceuticals: poised for a healthy slice of the healthcare market? *Nat Biotechnol.* 1998;16:728–31.
14. European Nutraceutical Association (ENA). Science behind Nutraceuticals. In E. N. Association (Ed.), (Vol. 2016). 2016;594 Basel, Switzerland.
15. Mobasher A. Intersection of inflammation and herbal medicine in the treatment of osteoarthritis. *Curr Rheumatol Rep.* 2012;14:604–16.
16. Ameye LG, Chee WSS. Osteoarthritis and nutrition. From nutraceuticals to functional foods: a systematic review of the scientific evidence *Arthritis Res Ther.* 2006;8:R127.
17. Henrotin Y, Lambert C, Couchourel D, Ripoll C, Chiotelli E. Nutraceuticals: do they represent a new era in the management of osteoarthritis? - a narrative review from the lessons taken with five products. *Osteoarthr Cartil.* 2011;19:1–21.
18. Gregory PJ, Fellner C. Dietary supplements as disease-modifying treatments in osteoarthritis: a critical appraisal. *P T.* 2014;39:436–52.
19. Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. *Br. J. Sports Med.* 2018;52:167–75. **This systematic review highlights the potential for using herbal supplements that demonstrate large effect sizes and clinically important effects for pain reduction at short term.**
20. Liu X, Eyles J, McLachlan AJ, Mobasher A. Which supplements can I recommend to my osteoarthritis patients? *Rheumatology.* 2018;57:iv75–iv87.
21. Akhtar N, Haqqi TM. Current nutraceuticals in the management of osteoarthritis: a review. *Ther Adv Musculoskelet Dis.* 2012;4:181–207.
22. Skov K, Oxfeldt M, Thøgersen R, Hansen M, Bertram HC. Enzymatic hydrolysis of a collagen hydrolysate enhances postprandial absorption rate—a randomized controlled trial. *Nutrients.* 2019;11.
23. ••Bagi CM, Berryman ER, Teo S, Lane NE. Oral administration of undenatured native chicken type II collagen (UC-II) diminished deterioration of articular cartilage in a rat model of osteoarthritis (OA). *Osteoarthr. Cartil.* 2017;25:2080–90 **This preclinical study in rats demonstrates that a daily dose of UC-II immediately after injury can improve the mechanical function of the injured joint and prevent excessive deterioration of articular cartilage.**

24. Lugo JP, Saiyed ZM, Lau FC, Molina JPL, Pakdaman MN, Shamie AN, et al. Undenatured type II collagen (UC-II®) for joint support: a randomized, double-blind, placebo-controlled study in healthy volunteers. *J Int Soc Sports Nutr.* 2013;10:48.
25. Gencoglu H, Orhan C, Sahin E, Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. *Animals (Basel).* 2020;10.
26. ••DeParle LA, Gupta RC, Canerdy TD, Goad JT, D'Altilio M, Bagchi M, et al. Efficacy and safety of glycosylated undenatured type-II collagen (UC-II) in therapy of arthritic dogs. *J Vet Pharmacol Ther.* 2005;28:385–90. **Canine study demonstrating that daily treatment of arthritic dogs with UC-II ameliorates signs and symptoms of arthritis, with no adverse effects.**
27. ••Gupta RC, Canerdy TD, Skaggs P, Stocker A, Zyrkowski G, Burke R, et al. Therapeutic efficacy of undenatured type-II collagen (UC-II) in comparison to glucosamine and chondroitin in arthritic horses. *J Vet Pharmacol Ther.* 2009;32:577–84. **Equine study demonstrating safety and efficacy of UC-II.**
28. Marone PA, Lau FC, Gupta RC, Bagchi M, Bagchi D. Safety and toxicological evaluation of undenatured type II collagen. *Toxicol Mech Methods.* 2010;20:175–89.
29. León-López A, Morales-Peñaloza A, Martínez-Juárez VM, Vargas-Torres A, Zeugolis DI, Aguirre-Álvarez G. Hydrolyzed collagen-sources and applications. *Molecules.* 2019;24.
30. Wang L, Wang Q, Liang Q, He Y, Wang Z, He S, et al. Determination of bioavailability and identification of collagen peptide in blood after oral ingestion of gelatin. *J Sci Food Agric.* 2015;95:2712–7.
31. Iwai K, Hasegawa T, Taguchi Y, Morimatsu F, Sato K, Nakamura Y, et al. Identification of food-derived collagen peptides in human blood after oral ingestion of gelatin hydrolysates. *J Agric Food Chem.* 2005;53:6531–6.
32. Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. *Nutr J.* 2016;15:14.
33. Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. *Int J Med Sci.* 2009;6:312–21.
34. Castro-Sánchez P, Martín-Villa JM. Gut immune system and oral tolerance. *Br. J. Nutr.* 2013;109 Suppl 2:S3-11.
35. Koh DR. Oral tolerance: mechanisms and therapy of autoimmune diseases. *Ann Acad Med Singap.* 1998;27:47–53.
36. Garside P, Mowat AM. Oral tolerance. *Semin Immunol.* 2001;13:177–85.
37. Worbs T, Bode U, Yan S, Hoffmann MW, Hintzen G, Bernhardt G, et al. Oral tolerance originates in the intestinal immune system and relies on antigen carriage by dendritic cells. *J Exp Med.* 2006;203:519–27.
38. Strober W, Kelsall B, Marth T. Oral tolerance. *J Clin Immunol.* 1998;18:1–30.
39. Wu HY, Weiner HL. Oral tolerance. *Immunol Res.* 2003;28:265–84.
40. Bagchi D, Misner B, Bagchi M, Kothari SC, Downs BW, Fafard RD, et al. Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. *Int J Clin Pharmacol Res.* 2002;22:101–10.
41. Pabst O, Mowat AM. Oral tolerance to food protein. *Mucosal Immunol.* 2012;5:232–9.
42. Di Cesare ML, Micheli L, Zanardelli M, Ghelardini C. Low dose native type II collagen prevents pain in a rat osteoarthritis model. *BMC Musculoskelet Disord.* 2013;14:228.
43. Osawa Y, Mizushige T, Jinno S, Sugihara F, Inoue N, Tanaka H, et al. Absorption and metabolism of orally administered collagen hydrolysates evaluated by the vascularly perfused rat intestine and liver in situ. *Biomed Res.* 2018;39:1–11.
44. ••Bello AE, Oesser S. Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders: a review of the literature. *Curr. Med. Res. Opin.* 2006;22:2221–32. **Comprehensive narrative review highlighting the potential for using collagen hydrolysates for treating OA.**
45. Oesser S, Seifert J. Stimulation of type II collagen biosynthesis and secretion in bovine chondrocytes cultured with degraded collagen. *Cell Tissue Res.* 2003;311:393–9.
46. ••Oesser S, Adam M, Babel W, Seifert J. Oral administration of (14)C labeled gelatin hydrolysate leads to an accumulation of radioactivity in cartilage of mice (C57/BL). *J. Nutr.* 1999;129:1891–5. **Preclinical study in mice demonstrating evidence of radiolabelled dietary gelatin in articular cartilage.**
47. Guillerminet F, Beaupied H, Fabien-Soulé V, Tomé D, Benhamou C-L, Roux C, et al. Hydrolyzed collagen improves bone metabolism and biomechanical parameters in ovariectomized mice: an in vitro and in vivo study. *Bone.* 2010;46:827–34.
48. Schauss AG, Stenehjem J, Park J, Endres JR, Clewell A. Effect of the novel low molecular weight hydrolyzed chicken sternal cartilage extract, BioCell Collagen, on improving osteoarthritis-related symptoms: a randomized, double-blind, placebo-controlled trial. *J Agric Food Chem.* 2012;60:4096–101.
49. Comblain F, Barthélémy N, Lefèbvre M, Schwartz C, Lespoune I, Serisier S, et al. A randomized, double-blind, prospective, placebo-controlled study of the efficacy of a diet supplemented with curcuminoids extract, hydrolyzed collagen and green tea extract in owner's dogs with osteoarthritis. *BMC Vet Res.* 2017;13:395.
50. van de Water E, Oosterlinck M, Dumoulin M, Korthagen NM, van Weeren PR, van den Broek J, et al. The preventive effects of two nutraceuticals on experimentally induced acute synovitis. *Equine Vet J.* 2017;49:532–8.
51. Dobenecker B, Reese S, Jahn W, Schunck M, Hugenberg J, Louton H, et al. Specific bioactive collagen peptides (PETAGILE®) as supplement for horses with osteoarthritis: a two-centred study. *J. Anim. Physiol. Anim. Nutr. (Berl).* 2018;102 Suppl 1:16–23.
52. Clark KL, Sebastianelli W, Flechsenhar KR, Aukermann DF, Meza F, Millard RL, et al. 24-Week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. *Curr Med Res Opin.* 2008;24:1485–96.
53. Walrand S, Chiotelli E, Noirt F, Mwewa S, Lassel T. Consumption of a functional fermented milk containing collagen hydrolysate improves the concentration of collagen-specific amino acids in plasma. *J Agric Food Chem.* 2008;56:7790–5.
54. ••Benito-Ruiz P, Camacho-Zambrano MM, Carrillo-Arcatales JN, Mestanza-Peralta MA, Vallejo-Flores CA, Vargas-López SV, et al. A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort. *Int J Food Sci Nutr.* 2009;60 Suppl 2:99–113. **A randomized, double-blind, controlled multicentre trial of 10 g of collagen hydrolysate consumed daily for 6 months in 250 human subjects with primary knee OA showing safety and efficacy.**
55. ••McAlindon TE, Nuite M, Krishnan N, Ruthazer R, Price LL, Burstein D, et al. Change in knee osteoarthritis cartilage detected by delayed gadolinium enhanced magnetic resonance imaging following treatment with collagen hydrolysate: a pilot randomized controlled trial. *Osteoarthr. Cartil.* 2011;19:399–405. **Imaging study using the dGEMRIC technique to demonstrate a change in proteoglycan content in patients consuming collagen hydrolysate for mild knee OA.**
56. ••McAlindon T, Bartnik E, S Ried J, Teichert L, Herrmann M, Flechsenhar K. Determination of serum biomarkers in osteoarthritis patients: a previous interventional imaging study revisited. *J Biomed Res.* 2016;31:25–30. **A serum biomarker study**


- demonstrating weak correlations between changes in biochemical markers in subjects who consumed collagen hydrolysates.**
57. Van Vlijven JJP, Luijsterburg PAJ, Verhagen AP, van Osch GJVM, Kloppenburg M, Bierma-Zeinstra SMA. Symptomatic and chondroprotective treatment with collagen derivatives in osteoarthritis: a systematic review. *Osteoarthr Cartil.* 2012;20:809–21.
 58. Schadow S, Simons VS, Lochnit G, Kordelle J, Gazova Z, Siebert H-C, et al. Metabolic response of human osteoarthritic cartilage to biochemically characterized collagen hydrolysates. *Int J Mol Sci.* 2017;18.
 59. Boonmaleeratt K, Wanachewin O, Phitak T, Pothacharoen P, Kongtawelert P. Fish collagen hydrolysates modulate cartilage metabolism. *Cell Biochem Biophys.* 2018;76:279–92.
 60. Koh A, Molinaro A, Ståhlman M, Khan MT, Schmidt C, Mannerås-Holm L, et al. Microbially produced imidazole propionate impairs insulin signaling through mTORC1. *Cell.* 2018;175:947–961.e17.
 61. Wu HJ, Ivanov II, Darce J, Hattori K, Shima T, Umesaki Y, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity.* 2010;32:815–27.
 62. Blacher E, Bashiardes S, Shapiro H, Rothschild D, Mor U, Dori-Bachash M, et al. Potential roles of gut microbiome and metabolites in modulating ALS in mice. *Nature.* 2019;572:474–80.
 63. Vich Vila A, Imhann F, Collij V, Jankipersadsing SA, Gurry T, Mujagic Z, et al. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. *Sci Transl Med.* 2018;10:eaap8914.
 64. Tyagi AM, Yu M, Darby TM, Vaccaro C, Li J-Y, Owens JA, et al. The microbial metabolite butyrate stimulates bone formation via t regulatory cell-mediated regulation of WNT10B expression. *Immunity.* 2018;49:1116–1131.e7.
 65. Rowland I, Gibson G, Heinken A, Scott K, Swann J, Thiele I, et al. Gut microbiota functions: metabolism of nutrients and other food components. *Eur J Nutr.* 2018;57:1–24.
 66. Schott EM, Farnsworth CW, Grier A, Lillis JA, Soniwal S, Dadourian GH, et al. Targeting the gut microbiome to treat the osteoarthritis of obesity. *JCI Insight.* 2018;3. **Review article highlighting the potential of manipulating the gut microbiome for the treatment of OA.**
 67. Favazzo LJ, Hendsi H, Villani DA, Soniwal S, Dar Q-A, Schott EM, et al. The gut microbiome-joint connection: implications in osteoarthritis. *Curr Opin Rheumatol.* 2020;32:92–101. **Review article highlighting the connection between joints, the gut microbiome and OA.**
 68. Liu F, Zhang N, Li Z, Wang X, Shi H, Xue C, et al. Chondroitin sulfate disaccharides modified the structure and function of the murine gut microbiome under healthy and stressed conditions. *Sci Rep.* 2017;7:6783.
 69. Shang Q, Yin Y, Zhu L, Li G, Yu G, Wang X. Degradation of chondroitin sulfate by the gut microbiota of Chinese individuals. *Int J Biol Macromol.* 2016;86:112–8.
 70. Ley RE, Bäckhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A.* 2005;102:11070–5.
 71. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. *Nature.* 2006;444:1022–3.
 72. Verhoeckx K, Cotter P, López-Expósito I, Kleiveland C, Lea T, Mackie A, et al. The impact of food bioactives on health. *Cham: Springer International Publishing.* 2015:103–11.
 73. Sadeghi Ekbatan S, Sleno L, Sabally K, Khairallah J, Azadi B, Rodes L, et al. Biotransformation of polyphenols in a dynamic multistage gastrointestinal model. *Food Chem.* 2016;204:453–62.
 74. Kubow S, Iskandar MM, Melgar-Bermudez E, Sleno L, Sabally K, Azadi B, et al. Effects of simulated human gastrointestinal digestion of two purple-fleshed potato cultivars on anthocyanin composition and cytotoxicity in colonic cancer and non-tumorigenic cells. *Nutrients.* 2017;9.
 75. Eckstein F, Hochberg MC, Guehring H, Moreau F, Ona V, Bihlet AR, et al. Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study. *Ann Rheum Dis.* 2021;80:1062–9.
 76. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin H-C, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. *Pharm Res.* 2006;23:1675–86.
 77. Musther H, Olivares-Morales A, Hatley OJD, Liu B, Rostami HA. Animal versus human oral drug bioavailability: do they correlate? *Eur J Pharm Sci.* 2014;57:280–91.
 78. Ayeahunie S, Landry T, Stevens Z, Armento A, Hayden P, Klausner M. Human primary cell-based organotypic microtissues for modeling small intestinal drug absorption. *Pharm Res.* 2018;35:72.
 79. Sadeghi Ekbatan S, Iskandar MM, Sleno L, Sabally K, Khairallah J, Prakash S, et al. Absorption and metabolism of phenolics from digests of polyphenol-rich potato extracts using the Caco-2/HepG2 co-culture system. *Foods.* 2018;7.
 80. Dupont D, Alric M, Blanquet-Diot S, Bornhorst G, Cueva C, Deglaire A, et al. Can dynamic in vitro digestion systems mimic the physiological reality? *Crit Rev Food Sci Nutr.* 2019;59:1546–62.
 81. Escudero E, Sentandreu MA, Toldrá F. Characterization of peptides released by in vitro digestion of pork meat. *J Agric Food Chem.* 2010;58:5160–5.
 82. Minekus M, Alving M, Alvito P, Ballance S, Bohn T, Bourlieu C, et al. A standardised static in vitro digestion method suitable for food - an international consensus. *Food Funct.* 2014;5:1113–24.
 83. Sayd T, Dufour C, Chambon C, Buffière C, Remond D, Santé-Lhoutellier V. Combined in vivo and in silico approaches for predicting the release of bioactive peptides from meat digestion. *Food Chem.* 2018;249:111–8.
 84. Possemiers S, Bolca S, Verstraete W, Heyerick A. The intestinal microbiome: a separate organ inside the body with the metabolic potential to influence the bioactivity of botanicals. *Fitoterapia.* 2011;82:53–66.
 85. Helal NA, Eassa HA, Amer AM, Eltokhy MA, Edafiohgo I, Nounou MI. Nutraceuticals' novel formulations: the good, the bad, the unknown and patents involved. *Recent Pat Drug Deliv Formul.* 2019;13:105–56.
 86. Mobasheri A, Rayman MP, Gualillo O, Sellam J, van der Kraan P, Fearon U. The role of metabolism in the pathogenesis of osteoarthritis. *Nat Rev Rheumatol.* 2017;13:302–11.
 87. Zheng L, Zhang Z, Sheng P, Mobasheri A. The role of metabolism in chondrocyte dysfunction and the progression of osteoarthritis. *Ageing Res Rev.* 2020;101249.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Ali Mobasher^{1,2,3,4,5}  · Armaghan Mahmoudian⁶  · Ursule Kalvaityte²  · Ilona Uzieliene²  ·
 Christina E. Larder⁷  · Michèle M. Iskandar⁷  · Stan Kubow⁷  · Paulo Cesar Hamdan⁸  ·
 Cyro Scala de Almeida Jr⁹  · Lacey J. Favazzo¹⁰ · Luc J.C. van Loon¹¹  · Pieter J. Emans¹²  · Pérola G. Plapler¹³  ·
 Michael J. Zuscik¹⁰ 

- ¹ Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland
- ² Department of Regenerative Medicine, State Research Institute, Centre for Innovative Medicine, Vilnius, Lithuania
- ³ Departments of Orthopedics, Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
- ⁴ Department of Joint Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong, China
- ⁵ World Health Organization Collaborating Center for Public Health Aspects of Musculoskeletal Health and Aging, Université de Liège, Liège, Belgium
- ⁶ Department of Clinical Sciences Lund, Orthopaedics, and Skeletal Biology, Clinical Epidemiology Unit, Lund University, Lund, Sweden
- ⁷ School of Human Nutrition, McGill University, 21,111 Lakeshore, Ste. Anne de Bellevue, QC H9X 3V9, Canada

- ⁸ Hospital Universitário Clementino Fraga Filho, Rheumatology Service, Orthopedics, Rheumatology and Physiatrics Center, Strength, Training Center, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
- ⁹ Santa Casa Sao Paulo, Sao Paulo, SP, Brazil
-  ¹⁰ Department of Orthopedics, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA
- ¹¹ Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands
- ¹² Department of Orthopaedic Surgery, CAPHRI School for Public Health and Primary Care, Maastricht University Medical Centre, Maastricht, The Netherlands
- ¹³ Instituto de Ortopedia e Traumatologia, Departamento de Fisiologia, Faculdade de Medicina (FMUSP), Universidade de Sao Paulo, Sao Paulo, SP, Brazil

11. Appendix 4: Newly allowed U.S. claims for Patent Application Serial No. 16/489,890

U.S. Patent Application Serial No. 16/489,890 Attorney Docket No. 614660: ROU9-002US

ALLOWED CLAIMS

1. A method of administering a prebiotic to a subject comprising administering to the subject a prebiotic composition comprising hydrolyzed collagen peptides, wherein the hydrolyzed collagen peptides are type 1 hydrolyzed collagen peptides (hCol1) originating from bovine, or type 2 hydrolyzed collagen peptides (hCol2) originating from porcine, wherein the hCol1 have a mean molecular weight between about 1800 Da and about 3500 Da and the hCol2 have a mean molecular weight between about 1300 Da and about 3000 Da.
2. The method of claim 1, wherein the gut microbiome in the subject is modulated.
3. The method according to claim 1, wherein microbial diversity in the gut is increased.
4. The method according to claim 1, wherein the composition comprises at least 90% or at least 95% by weight hydrolyzed collagen peptides, based on the dry mass of the composition.
- 5-7. **(Cancelled)**
8. The method according to claim 1, wherein said composition is formulated in a food or feed product, or a food or feed ingredient for oral administration.
9. The method according to claim 1, wherein said composition is formulated as a dietary supplement for oral administration.
10. The method according to claim 1, wherein said composition is administered to a subject each day for at least 7 days or for at least 14 days.
11. The method according to claim 1, wherein said composition is administered to the subject at a daily dosage of between 0.5g and 15g.

12. A method of preventing or treating joint inflammation in a subject comprising administering to the subject a composition comprising hydrolyzed collagen peptides, wherein the hydrolyzed collagen peptides are type 1 hydrolyzed collagen peptides (hCol1) originating from bovine, or type 2 hydrolyzed collagen peptides (hCol2) originating from porcine, wherein the hCol1 have a mean molecular weight between about 1800 Da and about 3500 Da and the hCol2 have a mean molecular weight between about 1300 Da and about 3000 Da.

13. The method according to claim 12, wherein the joint inflammation is synovial inflammation.

14. The method according to claim 12, wherein the composition comprises at least 90% or at least 95% by weight hydrolyzed collagen peptides, based on the dry mass of the composition.

15-17. **(Cancelled)**

18. A method for preventing or treating osteoarthritis in a subject, comprising administering to the subject a composition comprising hydrolyzed collagen peptides, wherein the hydrolyzed collagen peptides are type 2 hydrolyzed collagen peptides (hCol2) that originate from porcine collagen from cartilage, wherein the hCol2 have a mean molecular weight between about 1300 Da and about 3000 Da.

19. The method according to claim 18, wherein said osteoarthritis is posttraumatic osteoarthritis or obesity-induced osteoarthritis.

20. The method according to claim 18, wherein said composition comprises at least 90% or at least 95% by weight hydrolyzed collagen peptides, based on the dry mass of the composition.

21. **(Cancelled)**

22. A method of administering a chondroprotective agent to a subject comprising administering to the subject a composition comprising hydrolyzed collagen peptides, wherein the hydrolyzed collagen peptides are type 2 hydrolyzed collagen peptides (hCol2) originating from porcine, wherein the hCol2 have a mean molecular weight between about 1300 Da and about 3000 Da.

23. The method according to claim 22, wherein the composition comprises at least 90% or at least 95% by weight hCol2, based on the dry mass of the composition.

24. **(Cancelled)**

25. The method according to claim 22, wherein the hCol12 originates from porcine collagen from cartilage.

26-31. **(Cancelled)**